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a  b  s  t  r  a  c  t
Intranasal  live  attenuated  inﬂuenza  vaccine  (LAIV)  has  potential  for  self-administration  (SA)  by adults
and adolescents,  which  could  save  time  and  cost  in mass  vaccination  settings.  Participants  in a  study
of  LAIV  in  adults  (n = 4561)  selected  either  SA  or  health  care  provider  (HCP)  administration  and  were
followed  for febrile  illness  during  the  inﬂuenza  season.  More  LAIV  recipients  chose  SA-LAIV (72%)  than
HCP-LAIV  (28%).  Overall,  97%  of  SA-LAIV  and  98%  of  HCP-LAIV  recipients  had  no  problems  with  vaccineeywords:
ive attenuated inﬂuenza vaccine
elf administered
ffectiveness
administration.  Four  of  13  study  sites  enrolled  more  than  50  subjects  in both  cohorts.  Overall  and  for  these
4 sites,  illness  incidence  was  similar  with  SA-LAIV  and HCP-LAIV.  Solicited  reactogenicity  events  and
adverse  events  through  7  days  post  vaccination  were  comparable  for SA-LAIV  and  HCP-LAIV  recipients;
both  groups  exhibited  increased  runny  nose,  sore  throat,  and  cough  relative  to  placebo  recipients.  SA-
LAIV and  HCP-LAIV  appeared  similarly  effective  against  inﬂuenza-like  illness  and had  comparable  safety
proﬁles.
© 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.. Introduction
Inﬂuenza vaccine delivery requires vaccinating a large popu-
ation within a short time frame each year. Like other inﬂuenza
accines, intranasal live attenuated inﬂuenza vaccine (LAIV) is cur-
ently approved for administration by health care professionals
HCP); however, for adults and adolescents, self-administration
SA) could be more efﬁcient and less costly. These efﬁciencies could
e particularly important in urgent mass vaccination settings, such
s in response to a severe inﬂuenza epidemic or an inﬂuenza pan-
emic.
In 1997–1998, a randomized, placebo-controlled study was
onducted to evaluate the effectiveness of LAIV in preventing
nﬂuenza-like illness in U.S. adults 18–64 years of age [1].  As part
f the study protocol, subjects were allowed to choose between
upervised self-administration and HCP administration. The objec-
ive of the current analysis was to analyze the effectiveness and
afety of SA-LAIV compared with HCP-LAIV.
 This study was sponsored by MedImmune, LLC. Authors employed by MedIm-
une were involved in the study design, analysis, and interpretation of data, and in
he  preparation of the manuscript.
∗ Corresponding author at: MedImmune, LLC, One MedImmune Way,
aithersburg, MD  20878, USA. Tel.: +1 301 398 4454; fax: +1 301 398 9454.
E-mail address: ambrosec@medimmune.com (C.S. Ambrose).
264-410X     ©  2012 Elsevier Ltd. 
ttp://dx.doi.org/10.1016/j.vaccine.2012.12.028
Open access under CC BY-NC-ND license.2. Methods
2.1. Study design
The details of the original study methods have been described
previously [1].  Brieﬂy, 4561 adults 18–64 years of age were ran-
domized 2:1 to receive LAIV or placebo at 13 sites across the
United States and were followed during the inﬂuenza season for
the incidence of inﬂuenza-like illness. Subjects with high-risk
medical conditions were excluded and randomization was  bal-
anced by site. The primary endpoint was the incidence of any
febrile illness (AFI) during the inﬂuenza season. AFI constituted
≥2 consecutive days of symptoms with ≥1 day of fever or ≥2
symptoms (fever, chills, headache, runny nose, sore throat, cough,
muscle aches, tiredness/weakness) on ≥1 day. Secondary endpoints
included severe febrile illness (SFI, ≥3 consecutive days of symp-
toms, ≥1 day of fever, and ≥2 symptoms on ≥3 days) and febrile
upper respiratory illness (FURI, ≥2 consecutive days of upper res-
piratory tract symptoms, ≥1 day of fever, and 2 symptoms on
≥1 day). Specimens for laboratory identiﬁcation of inﬂuenza and
vaccine immunogenicity were not collected. Post vaccination reac-
togenicity symptoms and other unsolicited adverse events (AEs)
were collected by diary for 7 days following vaccination. After
receiving a single page of written administration instructions (see
Supplementary Fig.), each participant selected either SA or HCP
administration.
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Table 1
Characteristics of LAIV recipients by administration method.
Characteristic SA-LAIV
(n = 2026)
HCP-LAIV
(n = 805)
P value*
Age group, n (%)
<40 years 1202 (59) 389 (48) <0.0001
≥40 years 824 (41) 416 (52) –
Sex, n (%)
Male 919 (45) 336 (42) 0.0802
Female 1107 (55) 469 (58) –
Race, n (%)
White 1767 (87) 667 (83) 0.0026
Other 259 (13) 138 (17) –
Subjects with high-risk underlying medical conditions, n (%)
Yes 15 (1) 6 (1) 0.9889
No  2011 (99) 799 (99) –
Investigator site, n (%)
1 202 (10) 159 (20) <0.0001
2 108 (5) 45 (6) –
3  0 (0) 98 (12) –
4 26 (1) 1 (0) –
5  286 (14) 120 (15) –
6 206 (10) 2 (0) –
7  344 (17) 31 (4) –
8  217 (11) 1 (0) –
9  139 (7) 85 (11) –
10  184 (9) 30 (4) –
11 135 (7) 91 (11) –
12  31 (2) 130 (16) –
13 148 (7) 12 (1) –
Observation days, mean (SD) 47 (11.4) 44 (9.4) <0.0001
HCP, healthcare professional; LAIV, live attenuated inﬂuenza vaccine; SA, self-
T
R
H58 C.S. Ambrose, X. Wu / 
.2. Statistical analysis
The proportion of subjects selecting SA versus HCP adminis-
ration was calculated overall and by site. The analysis population
onsisted of subjects who received LAIV and had evaluable data for
FI, SFI, and FURI. The effectiveness of SA-LAIV relative to HCP-LAIV
as evaluated descriptively for sites with signiﬁcant enrollment in
oth groups. Using data from all sites, multiple variable logistic
egression analysis was conducted to compare the proportion of
A-LAIV and HCP-LAIV recipients experiencing AFI, SFI, and FURI.
xploratory variables included age (<40 vs. ≥40 years), gender, race
white vs. other), high risk (yes vs. no), and study site. The log of
he observation days was used as the offset variable. Safety was
ssessed by comparing solicited reactogenicity events (REs) and
ther AEs, including epistaxis events, within 7 days of vaccination.
. Results
Overall, 72% of LAIV recipients chose SA-LAIV (n = 2026) and 28%
hose HCP-LAIV (n = 805). Self-administration was chosen more
requently by younger subjects; 59% of SA-LAIV versus 48% of
CP-LAIV subjects were <40 years of age (P < 0.001), and 87% and
3% of SA-LAIV and HCP-LAIV subjects, respectively, were white
P < 0.003). SA-LAIV subjects had a longer duration of surveillance
uring site-speciﬁc inﬂuenza outbreak periods (47 vs. 44 days;
 < 0.001; Table 1). Across sites, the proportion of subjects selecting
elf-administration varied considerably, ranging from 0 to >99%.
our of 13 study sites (sites 1, 5, 9, and 11) enrolled >50 subjects
nder both administration methods. Overall, 96.7% and 98.3% of SA-
AIV and HCP-LAIV subjects, respectively, had no problems with
accine administration.
Across all study sites, without adjustment for confounders, ill-
ess rates were comparable for SA-LAIV and HCP-LAIV recipients,
lthough rates trended lower among HCP-LAIV recipients: AFI inci-
ence was 13.5% vs. 12.3% for SA-LAIV and HCP-LAIV, respectively;
FI incidence was 10.2% vs. 9.8%; FURI incidence was  8.6% vs. 8.2%.
mong the 4 study sites that enrolled more than 50 subjects under
oth administration methods (SA-LAIV, n = 762; HCP-LAIV, n = 455),
ates of AFI, FURI, and SFI during site-speciﬁc inﬂuenza outbreak
eriods were similar for SA-LAIV subjects and HCP-LAIV subjects
Fig. 1).
Using logistic regression to adjust data from all study sites for
otential confounding variables, the incidence of illness was  not
tatistically signiﬁcantly different between SA-LAIV and HCP-LAIV
ubjects. For AFI, the odds ratio for HCP-LAIV vs. SA-LAIV was 1.01
95% CI: 0.75, 1.35). For SFI and FURI, the odds ratios were 0.96 (95%
I: 0.69, 1.34) and 0.93 (95% CI: 0.65, 1.32), respectively.
Rates of reactogenicity events were comparable among SA-LAIV
nd HCP-LAIV subjects (Table 2). For both groups, the largest rate
ncreases relative to placebo were observed for runny nose and sore
able 2
eactogenicity events following vaccination among LAIV recipients by administration me
Reactogenicity event Number of reactogenicity ev
SA-LAIV (n = 2026) 
Runny nose 869 (42.9)*  
Headache 795 (39.2) 
Sore  throat 523 (25.8)*  
Tiredness/weakness 494 (24.4)*  
Muscle  aches 307 (15.2) 
Cough  274 (13.5)*  
Chills 159 (7.8) 
Fever  (oral temperature >100 F) 25 (1.2) 
CP, healthcare professional; LAIV, live attenuated inﬂuenza vaccine; SA, self-administer
∗ P < 0.05 vs. placebo.
† P = 0.04 for HCP-LAIV vs. SA-LAIV.administered.
∗ P value represents the comparison between SA-LAIV and HCP-LAIV using t test
for observation days and chi-square test for others.
throat. The rate of runny nose was  higher in HCP-LAIV versus SA-
LAIV recipients (P = 0.04). Regardless of treatment or administration
group, higher rates of reported runny nose, sore throat, headache,
chills, and tiredness/weakness were observed among female sub-
jects (P < 0.001 for all). Other unsolicited AEs were reported in 31.4%
of SA-LAIV and 29.9% of HCP-LAIV subjects (P = 0.47). Few cases of
epistaxis were reported, and rates of epistaxis were comparable for
SA-LAIV (0.3%) and HCP-LAIV (0.2%) recipients.
4. Discussion
This nonrandomized comparison of SA-LAIV and HCP-LAIV
suggests that both administration methods were similarly effec-
tive. Most study participants chose self-administration, and few
problems were reported. Reactogenicity events were similar in
both groups, with comparable increases in runny nose and sore
throat among LAIV recipients compared with placebo recipients.
The rate of runny nose was higher with HCP-LAIV versus SA-LAIV,
likely reﬂecting underlying differences in the 2 populations. In
thod relative to placebo recipients.
ents, n (%)
HCP-LAIV (n = 805) Placebo (n = 1420)
380 (47.2)*,† 372 (26.2)
312 (38.8) 535 (37.7)
217 (27.0)* 229 (16.1)
189 (23.5) 287 (20.2)
138 (17.1) 203 (14.3)
104 (12.9)* 139 (9.8)
66 (8.2) 88 (6.2)
8 (1.0) 17 (1.2)
ed.
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sig. 1. Relative risk of inﬂuenza-like illness for HCP-LAIV vs. SA-LAIV by site. AFI = a
AIV  = live attenuated inﬂuenza vaccine; SA = self-administered; SFI = severe febrile
articular, more female subjects chose HCP administration, and
emale subjects were more likely to report runny nose regardless
f administration method. Increased vaccine reactogenicity among
dult women has been observed previously with LAIV [2] and
ther vaccines [3–6]. Overall, reactogenicity proﬁles of SA-LAIV
nd HCP-LAIV are consistent with comparable vaccine-induced
mmune responses in each group. However, randomized compar-
sons of the effectiveness or immunogenicity of self-administration
nd HCP administration methods are needed to support routine
elf-administration of LAIV.
The feasibility of LAIV self-administration was  examined in a
tudy by the Kentucky Department of Health (Louisville, KY) [7]
n 2009. In a community walk-in immunization clinic, participants
elf-immunized in groups of 4–15 individuals after a short educa-
ional presentation by a nurse. A maximum of 124 individuals were
mmunized in 3 h. Two patients were not able to self-vaccinate due
o an anxiety disorder and a mild neuromuscular disorder. Side
ffects were reported by 2.7% of vacinees, and no serious side effects
ccurred. Among self-vaccinated individuals, 97% felt they used the
accine correctly, and 96% stated that they would self-administer
AIV in the future [7].
Self-administration has also been evaluated for intradermal
nactivated inﬂuenza vaccine. Coleman et al. randomized 228
dults 18–59 years to supervised self-administration versus nurse
dministration [8].  Successful administration on ﬁrst attempt was
eported for 93% of those self-administering, with 42% prefer-
ing self-administration in the future. Hemagglutination inhibition
iters 21 days following vaccination were similar in both groups,
nd less pain was reported by subjects who self-administered [8].
In this study, self-administration was performed under the
irect supervision of study staff. Supervised self-administration
nsures proper education on administration techniques and appro-
riate responses to any immediate adverse reactions, such as
ypersensitivity reactions. The prescribing information for LAIV [9]
tates that “appropriate medical treatment and supervision must
e available to manage possible anaphylactic reactions following
dministration of the vaccine.” Anaphylaxis and serious hypersen-
itivity following LAIV have been rare with <1 report per millionbrile illness; FURI = febrile upper respiratory illness; HCP = healthcare professional;
s. Symbol represents point estimate of the relative risk; lines represent 95% CIs.
doses with >50 million doses administered between 2003 and 2012.
Nevertheless, anaphylactic reactions are possible and appropriate
medical treatment should be available. For other disease condi-
tions that require treatment by injectable medications, such as
diabetes and rheumatoid arthritis, home self-administration has
become the standard of care [10–12].  However, unsupervised self-
administration is recommended to be initiated only after HCP
education on self-administration, potentially with an initial in-
ofﬁce administration.
There was  signiﬁcant variation across study sites in the propor-
tion of subjects who elected self-administration. This variability is
likely due to the manner in which site staff presented the option
to study participants. Despite this variability, the high proportion
that selected self-administration overall suggests a preference for
self-administration compared with administration by a HCP.
The primary limitation of the current analysis was the lack of
randomization of study subjects to SA-LAIV and HCP-LAIV. Because
of this limitation, there were signiﬁcant differences in SA-LAIV and
HCP-LAIV subjects, and analyses of AFI, SFI, and FURI incidence by
administration method had to be adjusted for potential confound-
ing variables. Differences due to study site were controlled in the
analysis through the exclusion of sites with fewer than 50 subjects
in each group; controlling for geographic location helped to mini-
mize bias due to local variability in respiratory virus activity. The
logistic regression analysis across all sites permitted adjustment
for study site and other confounding variables. Additionally, the
lack of laboratory conﬁrmation of inﬂuenza prevented an analysis
of inﬂuenza-speciﬁc illness.
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